


# KC cytokine treatments




(A)

PP-Increased DEGPs

PP-Decreased DEGPs

# KC gene perturbations




(B)

PP-Increased DEGPs

PP-Decreased DEGPs

# KC non-cytokine treatments




(C)

PP-Increased DEGs

PP-Decreased DEGs

# Fibroblast treatments




(D)

PP-Increased DEGPs      PP-Decreased DEGPs



# Psoriasis treatment responses




(E)

PP-Increased DEGs

PP-Decreased DEGs

# Mouse phenotypes




(F)

PP-Increased DEGs

PP-Decreased DEGs

# PBMC treatments




(G)

PP-Increased DEGs

PP-Decreased DEGs

# T-cell treatments




(H)

PP-Increased DEGs


PP-Decreased DEGs



# Dendritic cell treatments



# Macrophage treatments




(J)

PP-Increased DEGs

PP-Decreased DEGs

# Human skin diseases



(K)

PP-Increased DEGs

PP-Decreased DEGs